Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema
I'm PortAI, I can summarize articles.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced positive results from its ALPHA-SOLAR trial, which evaluated navenibart (STAR-0215) for hereditary angioedema (HAE). The trial showed a 95% reduction in monthly attack rates in the Q3M arm and an 86% reduction in the Q6M arm, indicating a favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress. Astria has also started the pivotal Phase 3 ALPHA-ORBIT trial to further assess navenibart’s efficacy and safety.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments